Dr. Lalitha Nayak, MD

Dr. Nayak practices at IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health.

Dr. Nayak's NPI, 1699803866, was assigned on March 1, 2007. Dr. Nayak holds Ohio license 35.097317.

Dr. Nayak's primary practice is IU Health Methodist Hospital, at 1701 N Senate Blvd, Indianapolis, IN 46202 in Marion County. The practice phone is (317) 962-2000.

Dr. Nayak's primary practice is IU Health Methodist Hospital in Indianapolis, Indiana, part of Indiana University Health. Dr. Nayak is also affiliated with Sidney & Lois Eskenazi Hospital. The medical group on file is IU Health Medical Group. Dmand AI also links Dr. Nayak to 1 more hospital, 2 group practices and clinics, 2 medical groups and 1 behavioral health center, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Nayak practices, 6 sites in all. Vendor and product names are available with a free account.

Hematology and oncology is Dr. Nayak's primary specialty in the NPI Registry, under taxonomy code 207RH0003X. Dmand AI has Dr. Nayak's licenses on file in 2 states: Ohio and Indiana.

CMS data shows 102 Medicare services from Dr. Nayak across 3 procedure codes in 2024, for 67 Medicare patients. Medicare paid $9,213 for them. Every service was in a facility, such as a hospital, rather than an office.

CMS counts 67 Medicare patients who saw Dr. Nayak in 2024. The largest group is 65 to 74, with 33 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 19% are also on Medicaid. Their average risk score is 2.43, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Nayak's median patient age at 51, with 59% women.

In 2024, Dr. Nayak wrote 41 Medicare Part D claims for 12 patients. Every claim was for a generic drug. CMS names the drug for 27 of them, across 2 drugs with 11 or more claims each, at $7,914 in total drug cost. In 2023, CMS named 12 claims across 1 drug.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 81 out of 100 for Dr. Nayak for performance year 2024, reported as part of a group. Dr. Nayak accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Nayak as offering telehealth.

Dmand AI links 41 papers to Dr. Nayak, published from 2010 to 2025. 2020 was the busiest year, with 7. The most frequent topics are Thrombosis, Kruppel-Like Transcription Factors and Mice, Inbred C57BL. Dr. Nayak has published most often in Blood. Dr. Nayak's most frequent co-authors are Alvin H. Schmaier, MD, Mouhamed Yazan Abou-Ismail, MD and Jane Allison Little, MD.

Dmand AI links Dr. Nayak to 1 clinical trial. 1 is still active or recruiting. Conditions studied include Anemia, Sickle Cell and Anemia, Hemolytic, Congenital.

CMS Open Payments shows 105 general payments to Dr. Nayak from 35 drug and device companies from 2016 to 2024. Consulting fees make up the largest share, 69% of the total. Alnylam Pharmaceuticals Inc. paid the most, $9,393.